All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Patient case discussion on treating with CELMoDs
During the Multiple Myeloma Hub Steering Committee Meeting in November 2023, key opinion leaders met to discuss patient cases on treatment with Cereblon E3 ligase modulator (CELMoDs). This recorded discussion was chaired by Paul Richardson and featured Sagar Lonial, María-Victoria Mateos, Heinz Ludwig, Hermann Einsele, Morie Gertz, Elena Zamagni, and Meral Beksac.
Patient case discussion on treating with CELMoDs
This session opened with a presentation from Paul Richardson in which they shared the mechanism of action, latest clinical data, and applications for CELMoDs in multiple myeloma. Richardson highlighted iberdomide and mezigdomide as novel agents and discussed the latest data from trials on their use both as monotherapies and in combination.
The panel discussed differences between the two agents, the incorporation of these drugs into the myeloma treatment landscape, and optimal combination treatments. The experts concluded by discussing the incidence of secondary malignancies associated with these agents and the applications of CELMoDs in extramedullary multiple myeloma.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox